home > products & services > the simcyp simulator
The Simcyp Simulator
The Simcyp Population-based Simulator streamlines drug development through the modelling and simulation of pharmacokinetics (PK) and pharmacodynamics (PD) in virtual populations. The Simulator is the pharmaceutical industry's most sophisticated platform for the prediction of drug-drug interactions and pharmacokinetic outcomes in clinical populations.
It contains numerous databases containing human physiological, genetic and epidemiological information. By integrating this information with your in vitro or clinical data, the Simulator allows you to predict PK/PD behaviour in ‘real-world’ populations. This automated prediction of in vivo outcomes accelerates the assessment of large numbers of compounds, saving time and cost.
The Simcyp Population-based Simulator provides valuable information for key management decisions relating to clinical trial design, clinical trial avoidance, and drug-drug interaction (DDI) information for the Summary of Product Characteristics (SPCs) and Prescribing Information sheets.
The Simcyp Simulator can also identify key pre-clinical data requirements, which can prove extremely valuable for redefining and optimising early drug development processes and procedures.
Simcyp Population-based Simulator, Version 11 (Release 2)
Extensive research and development has been performed in 2011 and several changes have been made to expand the capability of the Simulator including significant enhancements to simulation speed and memory usage. Recently implemented projects include:
- A Chinese population database: Simcyp’s virtual Chinese population accounts for differences in the genetic and physiological determinants of drug disposition between Chinese and Caucasian groups. Simulations can be performed in a general population as well as in healthy volunteers.
- Simcyp Mouse: A whole-body physiologically-based pharmacokinetic model for assessing PK properties, evaluating formulation and food effects on drug absorption, predicting concentration-time profiles in plasma, tissues and organs and investigating the formation and kinetics of primary metabolites. Virtual knock-in/knock-out mice can also be created allowing users to investigate how the addition or removal of specific genes controlling drug metabolising enzymes and transporters affects the ADME properties of a drug.
- Enhancements to Simcyp Paediatric: Users can now define distributions of neonates, infants, children and adolescents within simulations.
If you have any questions about Version 11 please do get in touch using the contact us form on the website.
Key features of the Simcyp Simulator:
- Fast
- User-friendly
- Up-to-date
- Transparent methods
- Cost-saving
- Time-saving
Key features |
Key benefits |
- Automated in vitro extrapolation to predict in vivo outcomes, supporting the assessment of large numbers of compounds metabolised by multiple enzymes
|
- Facilitates drug development by optimising the nomination of candidate drugs and the selection and design of in vivo studies, saving time and money
|
- Incorporates inter-subject physiological variability
|
- Allows prediction of drug disposition in real-world populations
|
- High speed, user friendly desk-top application
|
- Rapid identification of the mix of characteristics of individuals at greatest risk
|
- Batch processing facility
|
- Automates multiple simulations so a large number can be run in succession without further user input. This has proved particularly useful for sensitivity analysis.
|
- Transparent algorithms and methodology and easily understood visual outputs through a variety of graphics interfaces
|
- User-friendly and informative
|
- Incorporates leading-edge science with continually updated databases
|
- Your outputs are up-to-date, based on the latest scientific data
|
- Consortium members guide the development of the Simulator and share 'best practice'
|
- Simulator meets the current and future needs of the global pharmaceutical industry
|
- Supported by scientific and technical teams
|
- Help and advice at the end of the telephone
|
| |
|